Table 7 Prior to propensity score matching, neuromuscular blocking agent (NMBA) treatment, defined as 3 days of continuous use of NMBAs, within 48Â h from commencement of invasive mechanical ventilation, was associated with 90-day mortality (unadjusted Cox regression; HR 2.13, 95% CI 1.40, 3.24, PÂ <Â 0.001). After propensity-score matching, 50 patients who received NMBA treatment were matched with 50 controls (using replacement). Using the propensity score-matched cohort (and adjusting for covariates as per Table 4, NMBA therapy was not associated with 90-day mortality (adjusted HR 1.56 95% CI 0.55, 4.32, PÂ =Â 0.392)